TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study looked at lipid changes in human immunodeficiency virus type 1 (HIV-1) infected
patients when the nucleoside reverse transcriptase inhibitors (NRTIs) in their existing
highly active antiretroviral therapy (HAART) regimen were switched to Truvada® (a fixed dose
combination tablet of emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg [FTC/TDF]).
Subjects continued their nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease
inhibitor (PI) at the same dose.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Reverse Transcriptase Inhibitors